New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
Tools›Compare›PT-141 (Bremelanotide) vs Pinealon

PT-141 (Bremelanotide) vs Pinealon

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
PT-141 (Bremelanotide)
Cognitive EnhancementAnti-Aging & Longevity
Pinealon
Summary
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
Half-Life
2–3 hours
Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
Admin Route
SubQ
SubQ, Oral, Intranasal
Research
—
—
Typical Dose
0.5–1.75 mg
5–10 mg (oral) or 50–100 mcg (SC)
Frequency
As needed (not daily)
Once daily for 10 days
Key Benefits
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
  • Neuroprotection against oxidative stress and hypoxia
  • Promotes neuronal regeneration and repair
  • Improves memory and cognitive function
  • Enhances sleep quality via melatonin regulation
  • Anti-aging effects on brain cells
  • May slow cognitive decline in neurodegeneration
  • Improves cerebrovascular circulation
  • Reduces neuroinflammation
Side Effects
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
  • Excellent safety profile in clinical use
  • Rare: mild drowsiness
  • Transient mild headache at initiation
  • Injection site reaction (SC)
Stacks With
—
—